Financial Counselors Inc. Has $2.83 Million Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Financial Counselors Inc. reduced its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 47.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 18,829 shares of the medical research company's stock after selling 16,884 shares during the quarter. Financial Counselors Inc.'s holdings in Charles River Laboratories International were worth $2,834,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. Two Sigma Securities LLC boosted its holdings in Charles River Laboratories International by 4.3% during the fourth quarter. Two Sigma Securities LLC now owns 1,981 shares of the medical research company's stock valued at $366,000 after acquiring an additional 81 shares during the period. Wahed Invest LLC raised its position in shares of Charles River Laboratories International by 6.5% during the fourth quarter. Wahed Invest LLC now owns 1,321 shares of the medical research company's stock valued at $244,000 after buying an additional 81 shares during the last quarter. Jones Financial Companies Lllp raised its position in shares of Charles River Laboratories International by 16.3% during the fourth quarter. Jones Financial Companies Lllp now owns 641 shares of the medical research company's stock valued at $118,000 after buying an additional 90 shares during the last quarter. Nomura Asset Management Co. Ltd. raised its position in shares of Charles River Laboratories International by 0.7% during the fourth quarter. Nomura Asset Management Co. Ltd. now owns 15,694 shares of the medical research company's stock valued at $2,897,000 after buying an additional 102 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Charles River Laboratories International by 2.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,131 shares of the medical research company's stock worth $763,000 after purchasing an additional 105 shares in the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 500 shares of the company's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the transaction, the executive vice president owned 19,513 shares in the company, valued at approximately $2,837,385.33. This represents a 2.50% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on CRL shares. Barclays increased their price target on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 8th. Evercore ISI increased their price target on shares of Charles River Laboratories International from $170.00 to $180.00 and gave the company an "outperform" rating in a research note on Wednesday. Mizuho reduced their price target on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 9th. Redburn Atlantic raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and reduced their price target for the stock from $188.00 to $182.00 in a research report on Friday, May 23rd. Finally, Citigroup upgraded shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $150.00 to $200.00 in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $174.54.

Charles River Laboratories International Stock Down 2.4%

CRL stock traded down $3.88 during midday trading on Friday, hitting $159.78. The company's stock had a trading volume of 518,978 shares, compared to its average volume of 1,338,031. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.43 and a quick ratio of 1.16. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $254.15. The company's fifty day moving average price is $144.04 and its 200 day moving average price is $152.01. The stock has a market capitalization of $7.85 billion, a P/E ratio of -245.81, a PEG ratio of 5.38 and a beta of 1.49.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The company had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. During the same quarter last year, the firm posted $2.27 EPS. The company's quarterly revenue was down 2.7% on a year-over-year basis. As a group, equities research analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).